MMedXYNews
Ask AIHomeVideos
MedXY AI/MedXY News/Tag: relapsed AML

relapsed AML

Latest news

Tag

Hematology-Oncology

Enasidenib plus Venetoclax Shows Promising Activity in IDH2‑Mutant Relapsed/Refractory AML — ENAVEN‑AML Phase 1b/2 Results

The ENAVEN‑AML trial reports that enasidenib combined with venetoclax is feasible and active in relapsed/refractory IDH2‑mutant AML, achieving a 62% overall response rate with manageable toxicity but substantial infectious complications in

Nov 24, 2025
Hematology-Oncology

FDA Clears Second Menin Inhibitor — Ziftomenib (Komzifti) for Relapsed/Refractory NPM1‑Mutated AML

Ziftomenib is FDA-approved for adults with relapsed/refractory NPM1‑mutated AML based on single‑arm KOMET‑001 data showing a 22% remission rate and manageable toxicity including differentiation syndrome; randomized trials are planned to def

Nov 13, 2025

Most read

  1. 01Intimate Health

    Five Benefits for Women Continuing Sexual Activity After Menopause

  2. 02Intimate Health

    Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

  3. 03Nursing & care

    How often should a couple have sex?

  4. 04Cardiology

    Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval

  5. 05General Surgery

    Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Go deeper with MedXY AI

Explore the evidence behind the news.

Ask AI
MedXY briefing

Stay informed

Medical news and research updates, delivered to your inbox.

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story